Dr. Liang Ma 马良
Chief Physician
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of complex liver and gallbladder cases, including surgical, minimally invasive, comprehensive, and individualized therapies for liver tumors, bile duct tumors, and biliary stones.
Dr. Ma is Chief Physician and Head of the Liver and Biliary Ward at Guangxi Medical University Cancer Hospital. Holding a Master of Medicine, Dr. Ma serves as a master's supervisor. Research includes two National Natural Science Foundation projects and one Guangxi Natural Science Foundation project. Dr. Ma has received two Guangxi Science and Technology Progress First Prizes.
Professional roles
- Member, Biliary Tract Tumor Professional Committee, China Anti-Cancer Association
- Member, MDT Professional Committee, Chinese Branch of the International Hepato-Pancreato-Biliary Association
- Standing Committee Member, Liver Cancer Professional Committee, Guangxi Anti-Cancer Association
- Invited Editorial Board Member, Chinese Journal of Hepatology
Name order: in Chinese the family name comes first (Ma Liang). Papers usually list the name as Liang Ma or Ma L.
Selected publications
65 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Liver Cancer, 2026 (first author): Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006). PubMed 41551719
- Eur J Gastroenterol Hepatol, 2026 (senior author): Adjuvant camrelizumab for hepatocellular carcinoma patients with high risk of recurrence after curative hepatectomy: a retrospective multicenter study. PubMed 41870909
- Cancer Biol Med, 2025 (senior author): Comprehensive strategies for management of postoperative hyper-progression recurrence (HPR) of hepatocellular carcinoma: a 12-year large sample multi-center study. PubMed 40643201
- BMC Cancer, 2024 (senior author): Preoperative monocyte-to-lymphocyte ratio as a prognosis predictor after curative hepatectomy for intrahepatic cholangiocarcinoma. PubMed 39333901
- Intractable Rare Dis Res, 2022 (senior author): A case of hilar biliary cystadenoma with elevated IgG4 levels. PubMed 36200029
- Bioengineered, 2022 (senior author): Long non-coding RNA X-inactive specific transcript suppresses the progression of hepatocellular carcinoma through microRNA-221-3p-targeted regulation of O6-methylguanine-DNA methyltransferase. PubMed 35723009
- Future Oncol, 2022 (senior author): Influence of clear cell carcinoma on the post-hepatectomy prognosis of patients with hepatocellular carcinoma. PubMed 34878322
- Aliment Pharmacol Ther, 2021 (senior author): Letter: elevated HBV DNA predicts poor survival in hepatocellular carcinoma after hepatic resection. PubMed 33333596
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion